Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2483-2487

  Rastogi, Nalin ^a   Goh, Khye Seng ^a   Bryskier, André ^b,c   Devallois, Anne ^a  

^a Institut Pasteur de Guadeloupe   (Guadeloupe)

^b SANOFI   (France)

^c CENTRE HOSPITALIER VICTOR DUPOUY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLOFAZIMINE; ETHAMBUTOL; LEVOFLOXACIN; RIFAMPICIN; ROXITHROMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

EID: 10344232633     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2483     Document Type: Article

References (33)

1. Agnis, B. D., D. S. Berman, D. Spicehandler, W. El-Sadr, M. S. Simberkoff, and J. J. Rabal. 1989. Effect of combined therapy with anasamycin, clozazimine, ethambutol and isoniazid for Mycobacterium avium infection in patients with AIDS. J. Infect. Dis. 159:784-787.
2. Baron, E. J., and L. S. Young. 1986. Amikacin, ethambutol, and rifampin for treatment of disseminated Mycabacterium avium-intracellulare infections in patients with AIDS. Diagn. Microbiol. Infect. Dis. 5:215-220.
3. Barrow, W. W., E. L. Wright, K. S. Goh, and N. Rastogi. 1993. Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatly acid and peptide biosynthesis against Mycobacterium avium. Antimicrob. Agents Chemother. 37:652-661.
4. Bazile, S., N. Moreau, D. Bouzard, and M. Essiz. 1992. Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones. Antimicrob. Agents Chemother. 36:2622-2627.
5. Bermudez, L. E., C. B. Inderlied, P. Klonoski, M. Wu, L. Barabara-Burnham, and L. S. Young. 1996. Activities of Bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrob. Agents Chemother. 40:546-551.
6. Chiu, J., J. Nussbaum, S. Bozettz, J. G. Tilles, L. S. Young, J. Leedom, P. N. R. Heseltine, J. A. McCutchan, and California Collaborative Treatment Group. 1990. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann. Intern. Med. 113:358-361.
7. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barett, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
8. Goodwin, S. D., H. A. Gallis, A. T. Chow, F. A. Wong, S. C. Flor, and J. A. Bartlett. 1994. Pharmacokinetics and safely of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 38:799-804.
9. Hayakawa, I., S. Atarashi, S. Yokohama, M. Imamura, K. Sakano, and M. Furukawa. 1986. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob. Agents Chemother. 29:163-164.
10. Heifets, L. B., and P. J. Lindholm-Levy. 1987. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobaclerium avium complex. Tubercle 68:267-276.
11. Heifets, L. B., P. J. Lindholm-Levy, and R. D. Comstock. 1992. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am. Rev. Respir. Dis. 145:856-858.
12. Hoy, J., A. Mijch, M. Sandland, L. Grayson, R. Lucas, and B. Dwyer. 1990. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J. Infect. Dis. 161:801-805.
13. Immamura, M., S. Shibamura, I. Hayakawa, and Y. Osada. 1987. Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob. Agents Chemother. 31:325-327.
14. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobaclerium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
15. Klemens, S. P., C. A. Sharpe, M. C. Rogge, and M. H. Cynamon. 1994. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 38:1476-1479.
16. Mor, N., J. Vanderkolk, and L. Heifets. 1994. Inhibitory and bactericidal activities of Icvofloxacin against Mycobaclerium tuberculosis in vitro and in human macrophages. Antimicrob. Agents Chcmother. 38:1161-1164.
17. Nakashima, M., T. Uematsu, M. Kanamura, O. Okazaki, S. Hashimoto, and H. Tachizawa. 1988. Pharmacokinetics of DR-3355, a new quinolone, in healthy volunteers, abstr. 951, p. 278. In Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Neu, H. C., and N.-X. Chin. 1989. In vitro activity of S-ofloxacin. Antimicrob. Agents Chemother. 33:1105-1107.
19. Pascual, A., I. Garcia, and E. J. Perea. 1990. Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes. Antimicrob. Agents Chcmother. 33:653-656.
20. Pascual, A., I. Garcia, and E. J. Perea. 1990. Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob. Agents Chemother. 34:277-280.
21. Rastogi, N. 1993. Mycobacteria as intracellular pathogens: current notions of pathogenicity, virulence, and drug resistance and their relation to effective therapy, p. 245-300. In D. Raoult (ed.), Antimicrobial agents and intracellular pathogens. CRC Press, Inc., Boca Raton, Fla.
22. Rastogi, N., W. W. Barrow, C. O. Thoen, J. T. Crawford, B. T. Mangura, L. B. Reichman, L. B. Heifets, B. Dautzenberg, L. S. Young, L. E. M. Bermudez, C. B. Inderlied, A. E. Suzuki, J. M. Inamine, P. R. J. Gangadharam, M. V. Reddy, M. Denis, H. Shiratsuchi, J. L. Johnson, J. J. Ellner, J. T. Belisle, and P. J. Brennan. 1994. 11th Forum in Microbiology. Laboratory and clinical aspects of the Mycobacterium avium epidemic: contributing factors associated with variability of drug susceptibility and immune responsiveness, and the multifaceted nature of pathogenicity. Res. Microbiol. 145:167-261.
23. Rastogi, N., J. O. Falkinham, J. Grosset, C. A. Benson, C. F. Von Reyn, M. Pestel, R. D. Arbeit, R. J. Wallace, Jr., J. C. Sacchettini, J. S. Blanchard, U. Warek, S. T. Cole, E. Cambau, V. Jarlier, P. Sander, A. Meier, E. C. Böttger, S. L. Morris, D. A. Rouse, A. Telenti, D. H. Persing, S. Gordon, S. Houldsworth, K. Duncan, I. S. Roberts, P. W. Andrew, G. Klopman, D. Fercu, J.-Y. Li, H. S. Rosenkranz, M. R. Jacobs, K. S. Goh, S. Z. Van Ginkel, E. L. Wright, W. W. Barrow, J. A. Maddry, W. J. Sulinh, and R. C. Reynolds. 1996. 13th Forum in Microbiology. Solving the dilemma of antimycobacterial chemotherapy. Res. Microbiol. 147:7-121.
24. Rastogi, N., K. S. Goh, and A. Bryskier. 1993. In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs. Antimicrob. Agents Chemother. 37:1560-1562.
25. Rastogi, N., K. S. Goh, and A. Bryskier. 1994. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Antimicrob. Agents Chemother. 38:1433-1438.
26. Rastogi, N., and V. Labrousse. 1991. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob. Agents Chemother. 35:462-470.
27. Rastogi, N., V. Labrousse, and A. Bryskier. 1995. Intracellular activities of roxithromycin used alone and in combination with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob. Agents Chemother. 39:976-978.
28. Rastogi, N., V. Labrousse, K. S. Goh, and J. P. Carvalho de Sousa. 1991. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob. Agents Chemother. 35:2473-2480.
29. Saito, H., K. Sato, H. Tomioka, and S. Dekio. 1995. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tubercle Lung Dis. 76:377-380.
30. Skinner, P. S., S. K. Furney, D. A. Kleinert, and I. A. Orme. 1995. Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:750-753.
31. Tanaka, M., M. Otsuki, T. Une, and T. Nishino. 1990. In vitro and in vivo activity of DR-3355, an optically active isomer of ofloxacin. J. Antimicrob. Chemother. 26:659-666.
32. Tulkens, P. M. 1991. Intracellular distribution and activity of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:100-106.
33. Une, T., T. Fujimoto, K. Sato, and Y. Osada. 1988. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob. Agents Chemother. 32: 1336-1340.